Aakaar FY26: A credit reset in H1, a profitability rebound in H2

Aakaar Medical Technologies Limited, India’s first NSE-listed medical aesthetics company, closed FY2025-26 with revenue from operations of INR 66.9 Cr, EBITDA of INR 10.97 Cr, and PAT of INR 6.63 Cr. The year delivered steady growth on the headline numbers with revenue up 8.6 percent YoY, EBITDA up 12 percent YoY, and PAT up 10 percent YoY. But the bigger story sits inside the year. H1FY26 was intentionally slowed by tighter credit and a shift toward cash-first billing, while H2FY26 showed what the model can look like when volumes recover under stricter working-capital controls.

On a half-year basis, H2FY26 revenue rose to INR 41.6 Cr from INR 25.3 Cr in H1FY26, a 64.4 percent H-o-H jump. EBITDA moved from a near-flat INR 0.02 Cr in H1FY26 to INR 10.95 Cr in H2FY26, taking margins from 0.07 percent to 26.32 percent. PAT turned around from a loss of INR 0.8 Cr in H1FY26 to a profit of INR 7.4 Cr in H2FY26. Management links this swing to a deliberate clean-up of credit practices, a more precise procurement approach after a period of inventory build-up, and normalization after one-off business development costs that were concentrated in the first half.

Aakaar’s operating model is built around a recurring, product-led engine. Aesthetic products form the base, with products at 89 percent plus device consumables at 4 percent described as recurring in nature. The company also sells aesthetics devices and device consumables, but the core annuity comes from in-clinic products and homecare ranges that flow repeatedly through the doctor network. This structure matters because it shapes how revenue returns after a credit tightening. Once doctors and clinics adapt to new billing discipline, recurring demand can reassert itself without the same need to chase incremental volume through loose terms.

The FY26 numbers and what changed inside the year

The FY26 P and L points to a business that expanded gross profitability while absorbing higher operating costs. Revenue from operations increased to INR 66.9 Cr from INR 61.6 Cr in FY25. COGS rose to INR 28.20 Cr, resulting in gross profit of INR 39.5 Cr and a gross margin of 59.34 percent, up from 57.6 percent in FY25. On the cost line, employee benefits expense increased to INR 14.0 Cr from INR 12.9 Cr, and other expenses increased to INR 14.5 Cr from INR 12.83 Cr. Even with these higher costs, EBITDA rose to INR 10.97 Cr and the EBITDA margin expanded to 16.39 percent from 15.97 percent.

The half-year split shows why the annual view can be misleading. H1FY26 was the transition phase. Revenue softened because the company tightened credit terms to strengthen long-term cash flow and working capital discipline. Profitability was held back by business development cost, operating expenses, and one-off investments that were front-loaded. There was also a tactical inventory build in H1, attributed to war-related uncertainty and the company’s conversion from private limited to limited.

H2FY26 shows the payback. Management highlights that customers returned and demand was restored while keeping credit controls in place. Procurement was tied to demand visibility and confirmed orders, which helped reduce excess stock. The company also notes that remaining year-end inventory was cleared in April.

One operational metric underlines the tightening effort. Debtor days reduced from 209 in Jun-25 to 167 in Mar-26. That reduction is meaningful because Aakaar’s business depends on repeat purchases across a wide base of doctors and clinics, and that base can absorb changes in credit policy if the supply chain remains reliable and the product mix stays relevant.

Segment momentum and the compounding effect of breadth

Aakaar positions itself as a comprehensive platform across aesthetics products, devices, and device consumables, serving professional in-clinic and at-home use. Within products, the company covers professional skin care, professional hair care, injectables and contouring, and home care for skin and hair. This breadth shows up in the segment growth numbers over the last three years.

Between FY23 and FY26, professional skincare grew from INR 9 Cr to INR 20 Cr, and injectables and contouring grew from INR 8 Cr to INR 18 Cr, both with a stated CAGR of 31 percent. Homecare for skin and hair increased from INR 5 Cr to INR 11 Cr, with a stated CAGR of 30 percent. Professional haircare moved from INR 1 Cr to INR 11 Cr with a stated CAGR of 122 percent, which suggests a category that is still scaling from a low base. Devices and device consumables grew more slowly from INR 6 Cr to INR 7 Cr, with a stated CAGR of 5 percent.

The company’s portfolio strength is reflected in the concentration data it shares for products. The top 10 own products contributed 27 percent of revenue from operations in FY26, up from 24 percent in FY25 and 17 percent in FY23. Top 10 imported products contributed 51 percent in FY26, up from 48 percent in FY25. This combination indicates that a limited set of strong franchises drive a large portion of sales, but the mix is gradually tilting toward Aakaar’s own products.

Among the top FY26 products by revenue, Inno Exfo Lightening in professional skin care is shown at INR 13.04 Cr. TUBELITE GFC 360 Kit is shown at INR 8.53 Cr under injectables and contouring. Several dermal filler SKUs also appear in the top 10, including Saypha variants and Siax.

The distribution footprint gives context for how this breadth converts to repeat orders. Aakaar reports 6,300 plus customers in FY26 and a customer expansion of 20 percent from 5,236 to 6,300 plus. It also reports 100 plus MR executives, 52 plus stockists, and 1,000 plus pharmacies, alongside a doctor-dispensed model that emphasizes trust and feedback loops. In addition, the company highlights reduced reliance on top 10 customers, which is consistent with a strategy of broad-based coverage.

Execution after listing: cash discipline, supply chain redesign, and product mix

The strategic shift described post listing is anchored in cash discipline. Management frames H1’s slowdown as deliberate, tied to tighter credit terms and a move toward cash-first billing. That trade-off is common in distribution-led businesses. Revenue can soften in the short term, but the quality of sales improves and the business becomes easier to scale without working-capital stress.

Aakaar also describes an operational move in distribution. In FY25-26, it ran a mix of distribution models, including a CFA setup through Novacare and a self warehouse in Andheri. For FY26-27, the company signals a change toward Aakaar to CFA to distributors. In parallel, it states a direction to move to 90 percent plus sales through stockists in FY26-27, from a reported mix that includes direct-to-doctor sales at 65 percent and doctor from stockist at 35 percent. The rationale is explicit: a more robust logistics supply chain, under 24-hour delivery, and trade receivables improvement through local multi-distributor control on overdues.

The financial impact of working-capital tightening is visible in the balance sheet. Cash and bank balance increased to INR 16.2 Cr in FY26 from INR 5.6 Cr in FY25. At the same time, trade receivables increased to INR 37.22 Cr from INR 28.0 Cr, and inventories increased to INR 19.7 Cr from INR 14.6 Cr. This combination suggests that while cash rose sharply, the company still carried a higher receivables and inventory base at year-end, which makes the debtor-day reduction and inventory clearance commentary important.

Management also emphasizes product mix as a lever for margin durability. It states that low-margin products are being phased out in favor of high-margin SKUs with strong gross contributions. The result is expected to be leaner operations, higher operating profit, and sustained PAT improvement. The FY26 gross margin of 59.34 percent, up from 57.6 percent in FY25, supports this direction, even though cost lines rose.

A product pipeline and launch strategy sits behind this. The company outlines a typical 9 to 12 month timeline to launch own brands, and an 18 to 24 month cycle for imported products due to regulatory steps. This cadence matters because Aakaar is balancing two sources of growth: in-licensed international brands that contribute a majority of topline, and a growing share of own brands that can lift margins and build defensibility.

Portfolio building and the next leg: four launches and Xelix platform

The presentation highlights four launches positioned as one strategy for a dominant aesthetics ecosystem. It lists LETYBO as a neuromodulator, SAYPHA as a dermal filler, VM Corporation as a regenerative suite with a three-product Italian exosome range, and XOMAGE as a plant exosome platform. The unifying idea is to deepen the company’s presence in higher-value aesthetics categories and to strengthen its premium and differentiated offerings.

Alongside product launches, Aakaar has invested in skill-building and market creation through training. Its MICA program trains and certifies dermatologists and students across dermal fillers, threads, and toxins. The company reports 75 plus workshops conducted, 574 plus professionals trained, and 44 plus cities ventured, and notes that a trichology workshop started in FY25-26. In medical aesthetics, consistent training can act as a demand driver because adoption often depends on practitioner confidence and outcomes.

A newer strategic layer is the XELIX platform, described as India’s first doctor-owned, doctor-operated medical aesthetics platform, backed by Aakaar Medical Technologies Ltd. The platform is positioned around clinical SOPs, diagnostics, proprietary technologies, and a doctor value stack designed to be zero capex for partner clinics. The presentation states 16 active clinics and a roadmap that scales from 50 clinics in FY26 to 100 plus clinics in FY27, and ultimately 500 clinics in the future across hair, skin, and body. It also lists an active network of doctors with locations across multiple cities.

For investors, the key question is not whether platforms sound compelling, but whether they can scale without distracting from the core distribution engine. Aakaar’s positioning suggests it wants Xelix to sit on top of its existing B2B backbone, using the same supply chain and relationships. If execution stays disciplined, the platform can deepen pull-through demand for products and homecare ecosystems, and add more recurring revenue streams.

What investors should take away

FY26 for Aakaar reads as a year of internal reset and second-half proof. Revenue growth of 8.6 percent YoY and PAT growth of 10 percent YoY reflect steady expansion, but the H1 to H2 swing shows the operational leverage that can appear once credit tightening and procurement discipline settle in. The H2FY26 EBITDA margin of 26.32 percent is not a full-year run-rate, but it is a useful signal of what profitability can look like when sales return and one-offs fade.

The second takeaway is that working-capital discipline is now part of the company’s strategy rather than a periodic clean-up. Debtor days moved down from 209 to 167 between Jun-25 and Mar-26, and the distribution model is being redesigned to push more volume through stockists, which management links directly to better receivables control and faster delivery.

Third, the portfolio is being shaped for both growth and margin resilience. International in-licensing remains central and is described as contributing 70 percent of topline, but own brand revenue is shown at INR 24.57 Cr in FY26 and is described as 37 percent, reinforcing the shift to owned franchises. Segment growth trends show that injectables, professional skincare, homecare, and professional haircare are expanding faster than devices.

Aakaar ends FY26 with higher cash, higher scale, and a clearer operating stance. If the company sustains stricter billing, keeps procurement tied to demand visibility, and executes the channel shift without losing momentum, the next phase is less about chasing growth and more about making growth easier to fund.